Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback